Brazil's HIV/AIDS treatment, prevention program may be in jeopardy, some experts say

The Miami Herald reports on Brazil's national HIV/AIDS treatment and prevention program, writing, "By the mid-1990s, more effective and powerful antiretroviral therapies replaced the older treatments, and in 1996 Brazil declared that it would offer free antiretroviral treatment to all citizens with AIDS." However, "the controversial program -- the government broke international patent laws to mass-produce the drugs at a lower cost and recruited sex workers to help distribute condoms -- may not survive for long, experts say," the newspaper continues.

"AIDS activists fear that costs will rise for the Brazilian government as patients on the life-saving treatment live longer than they did in the past, according to the U.S. Agency for International Development and the Joint United Nations Program on HIV/AIDS," the Miami Herald notes. "Richard Parker, an American medical anthropologist and the president of the Brazilian Interdisciplinary AIDS Association, also says there's less support from the government under President Dilma Rousseff than there was under her predecessor, Luiz Inacio Lula da Silva, better known as Lula," the newspaper writes. "The issue is that Brazil had, clearly, what was a model for the response to AIDS in the developing world," Parker said, adding, "That model program is now in jeopardy," according to the newspaper (Minemyer, 6/12).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Affordability and supply remain critical to the success of long-lasting HIV drug